SB431542 treatment promotes the hypertrophy of skeletal muscle fibers but decreases specific force

K. I. Watt, R. T. Jaspers, P. Atherton, K. Smith, M. J. Rennie, Aivaras Ratkevicius, Henning Wackerhage

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The small molecule inhibitor SB431542 inhibits activin type I receptors. The muscle growth-inhibitor myostatin binds to and signals via these receptors. The aim of this study was to test the hypothesis that SB431542 can inhibit myostatin-related Smad signaling and induce muscle growth in cultured C2C12 myotubes and increase growth and specific force in cultured Xenopus muscle fibers. The effect of SB431542 was assessed in vitro on C2C12 myotubes and ex vivo using mature Xenopus muscle fibers. SB431542 treatment reduced myostatin-induced C-terminal Smad2 phosphorylation and resulted in the formation of enlarged myotubes. However myogenin expression was unchanged, while p70 S6k phosphorylation at Thr389, total myosin heavy chain, and the rate of protein synthesis were all reduced. Mature Xenopus muscle fibers that were treated with SB431542 had a higher fiber cross-sectional area but decreased specific force production than control. SB431542 can initially antagonize myostatin signaling, but long-term unexpected signaling effects occur. Muscle fibers hypertrophy, but their specific force decreases compared to control.
Original languageEnglish
Pages (from-to)624-629
Number of pages5
JournalMuscle & nerve
Volume41
Issue number5
Early online date11 Feb 2010
DOIs
Publication statusPublished - May 2010

Keywords

  • Hypertrophy
  • Myostatin
  • SB431542
  • Skeletal muscle
  • Smad

Fingerprint Dive into the research topics of 'SB431542 treatment promotes the hypertrophy of skeletal muscle fibers but decreases specific force'. Together they form a unique fingerprint.

Cite this